Loading
Diet, Metabolism, and Disease · Journal article
Cancers · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a critical narrative review of ketogenic metabolic therapy in epithelial cancers that synthesizes mechanistic evidence from preclinical work and observes clinical feasibility and quality-of-life improvements, but explicitly notes that robust evidence for survival benefit is limited and heterogeneous. The authors argue the field lacks integration of tumor metabolism, host physiology, and microenvironment, and propose that ketogenic interventions should be viewed as stratified, biomarker-guided approaches rather than universal therapies.
Narrative review. Patients with epithelial cancers (review scope); no primary study population enrolled.
Preclinical evidence shows anti-proliferative and immunomodulatory effects of ketogenic metabolic therapy Clinical studies demonstrate KMT is generally feasible and associated with improvements in quality of life and metabolic parameters Robust evidence for survival benefit of KMT remains limited and heterogeneous across clinical studies
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not regard ketogenic interventions as a universal adjuvant therapy pending biomarker-driven patient selection and improved experimental models. The heterogeneity of clinical results and limited survival evidence argue against routine adoption without stratification.
This is a narrative review synthesizing preclinical mechanisms and heterogeneous clinical evidence without new primary data, raising mechanistic questions about ketogenic metabolic therapy in cancer rather than answering them with controlled evidence.
As stated by the source record.
Clinicians should not regard ketogenic interventions as a universal adjuvant therapy pending biomarker-driven patient selection and improved experimental models. The heterogeneity of clinical results and limited survival evidence argue against routine adoption without stratification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Ketogenic metabolic therapy (KMT), typically implemented as a ketogenic diet (KD), has re-emerged as a potential adjuvant strategy in oncology. Its rationale is grounded in the metabolic reprogramming of cancer cells, including their reliance on glucose and lipid substrates and the signaling functions of ketone bodies. Despite extensive preclinical evidence of anti-proliferative and immunomodulatory effects, clinical translation in cancer therapy has been slow and inconsistent. This review critically examines the mechanistic basis, experimental and clinical evidence, and translational challenges of KMT across epithelial cancers. We emphasize that “ketogenic interventions” comprise mechanistically distinct modalities, including classical KD, fasting, fasting-mimicking diets, and exogenous ketone supplementation, which are frequently conflated yet differ substantially in their endocrine and metabolic contexts. Across clinical studies, KMT is generally feasible and associated with improvements in quality of life and metabolic parameters; however, robust evidence for the survival benefit of KMT remains limited and heterogeneous. Mechanistically, ketone bodies exert both metabolic and signaling functions, including inhibition of histone deacetylases, lysine β-hydroxybutyrylation, and receptor-mediated effects. Tumor responses are highly context-dependent: ketolytic capacity, governed by enzymes such as OXCT1, can render ketones either a metabolic vulnerability or an alternative fuel for cancer cells. KMT can modify the complex tumor microenvironment, exerting potentially opposing effects on cancer cells, immune cell populations, fibroblasts, and adipocytes. We argue that the central limitation of the field is not a lack of biological activity, but of insufficient integration of tumor-intrinsic metabolism, host physiology, and microenvironmental context. KD/KMT should therefore be regarded not as a universal anticancer therapy, but as a stratified metabolic intervention, whose progress will depend on biomarker-guided patient selection, improved experimental models, and rational combination strategies within a “press-pulse” therapeutic framework.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.